{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:06:25Z","timestamp":1791860785252,"version":"4.3.4"},"reference-count":280,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2009,6,3]],"date-time":"2009-06-03T00:00:00Z","timestamp":1243987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The term neurodegenerative disorders, encompasses a variety of underlying conditions, sporadic and\/or familial and are characterized by the persistent loss of neuronal subtypes. These disorders can disrupt molecular pathways, synapses, neuronal subpopulations and local circuits in specific brain regions, as well as higher-order neural networks. Abnormal network activities may result in a vicious cycle, further impairing the integrity and functions of neurons and synapses, for example, through aberrant excitation or inhibition. The most common neurodegenerative disorders are Alzheimer\u2019s disease, Parkinson\u2019s disease, Amyotrophic Lateral Sclerosis and Huntington\u2019s disease. The molecular features of these disorders have been extensively researched and various unique neurotherapeutic interventions have been developed. However, there is an enormous coercion to integrate the existing knowledge in order to intensify the reliability with which neurodegenerative disorders can be diagnosed and treated. The objective of this review article is therefore to assimilate these disorders\u2019 in terms of their neuropathology, neurogenetics, etiology, trends in pharmacological treatment, clinical management, and the use of innovative neurotherapeutic interventions.<\/jats:p>","DOI":"10.3390\/ijms10062510","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T04:00:31Z","timestamp":1244174431000},"page":"2510-2557","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders"],"prefix":"10.3390","volume":"10","author":[{"given":"Yahya  E.","family":"Choonara","sequence":"first","affiliation":[{"name":"University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, Parktown, 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-3347","authenticated-orcid":false,"given":"Viness","family":"Pillay","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, Parktown, 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa  C.","family":"Du Toit","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, Parktown, 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Modi","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Department of Neurology, 7 York Road, Parktown, 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Naidoo","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Department of Neurosurgery, 7 York Road, Parktown, 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valence  M.K.","family":"Ndesendo","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, Parktown, 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibongile  R.","family":"Sibambo","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, Parktown, 2193, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2009,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jama.285.5.594","article-title":"Prospects for neurology and psychiatry","volume":"285","author":"Cowan","year":"2001","journal-title":"J. Am. Med. Assoc"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1212\/01.WNL.0000147264.60349.EB","article-title":"No association of the SOD1 locus and disease susceptibility or phenotype in sporadic ALS","volume":"63","author":"Broom","year":"2004","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clinph.2004.11.017","article-title":"Motor cortex dysfunction revealed by cortical excitability studies in Parkinson\u2019s disease: Influence of antiparkinsonian treatment and cortical stimulation","volume":"116","author":"Lefaucheur","year":"2005","journal-title":"Clin. Neurophysiol"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1471-4159.2004.02864.x","article-title":"Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer\u2019s disease and link to cognitive impairment","volume":"92","author":"Ahmed","year":"2005","journal-title":"J. Neurochem"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-005-0597-2","article-title":"Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer\u2019s disease","volume":"252","author":"Ivanoiu","year":"2005","journal-title":"J. Neurol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1212\/01.WNL.0000149513.82332.5C","article-title":"Physical activity and the association with sporadic ALS","volume":"64","author":"Veldink","year":"2005","journal-title":"Neurol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu. Rev. Neurosci"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/01.WNL.0000130198.72589.69","article-title":"Prion protein codon 129 polymorphism and risk of Alzheimer disease","volume":"63","author":"Riemenschneider","year":"2004","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/NEN.0b013e31818b4126","article-title":"Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb","volume":"67","author":"Sengoku","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0896-6273(94)90264-X","article-title":"Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer\u2019s disease paired helical filament tau","volume":"13","author":"Matsuo","year":"1994","journal-title":"Neuron"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.bbrc.2004.11.106","article-title":"Down-regulation of MHC class I expression in human neuronal stem cells using viral stealth mechanism","volume":"326","author":"Lee","year":"2005","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1007\/PL00012495","article-title":"Functions and malfunctions of the tau proteins","volume":"59","author":"Shahani","year":"2002","journal-title":"Cell Mol Life Sci"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI200420640","article-title":"Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology","volume":"14","author":"Rissman","year":"2004","journal-title":"J. Clin. Invest"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbadis.2004.06.019","article-title":"Can tau filaments be both physiologically beneficial and toxic?","volume":"1739","author":"King","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1385\/NMM:4:1-2:109","article-title":"Perturbed signal transduction in neurodegenerative disorders involving aberrant protein aggregation","volume":"4","author":"Mattson","year":"2003","journal-title":"Neuro. Mol. Med"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/35037739","article-title":"Apoptosis in the nervous system","volume":"407","author":"Yuan","year":"2000","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.278.5337.412","article-title":"Life and death of neurons in the aging brain","volume":"278","author":"Morrison","year":"1997","journal-title":"Sci"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1531-8249(20010201)49:2<202::AID-ANA40>3.0.CO;2-3","article-title":"Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment","volume":"49","author":"Kordower","year":"2001","journal-title":"Ann. Neurol"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S0317167100003309","article-title":"Antipsychotic drug-induced movement disorders","volume":"30","author":"Blanchet","year":"2003","journal-title":"Can. J. Neurol. Sci"},{"key":"ref_20","first-page":"283","article-title":"Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the \u2018Dr. Jekyll and Mr. Hyde concept\u2019 of Alzheimer\u2019s disease or the yin and yang of neuroplasticity","volume":"71","author":"Arendt","year":"2001","journal-title":"Prog. Neurobiol"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nature05289","article-title":"A network dysfunction perspective on neurodegenerative diseases","volume":"443","author":"Palop","year":"2006","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archneur.58.9.1395","article-title":"Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease","volume":"58","author":"Price","year":"2001","journal-title":"Arch. Neurol"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/archneur.63.4.584","article-title":"Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra","volume":"63","author":"Greffard","year":"2006","journal-title":"Arch. Neurol"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Ann. Neurol"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0002-9343(00)00291-6","article-title":"Apoptosis and neurologic disease","volume":"108","author":"Honig","year":"2000","journal-title":"Am. J. Med"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1568007043337210","article-title":"Natural and synthetic inhibitors of caspases: Targets for novel drugs","volume":"3","author":"Onteniente","year":"2000","journal-title":"Curr. Drug Targ. CNS Neurol. Disord"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1046\/j.1471-4159.2002.00928.x","article-title":"Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson\u2019s disease","volume":"81","author":"Gao","year":"2002","journal-title":"J. Neurochem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00726-003-0048-2","article-title":"Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach","volume":"25","author":"Calabrese","year":"2003","journal-title":"Amino Acids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1073\/pnas.0308224100","article-title":"Microtransplantation of functional receptors and channels from the Alzheimer\u2019s brain to frog oocytes","volume":"101","author":"Miledi","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.expneurol.2003.09.021","article-title":"Aberrant expressions of pathogenic phenotype in Alzheimer\u2019s disease transgenic mice carrying NSE-controlled APPsw","volume":"186","author":"Hwang","year":"2004","journal-title":"Exp. Neurol"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/sim.1718","article-title":"The evaluation of disease modifying therapies in Alzheimer\u2019s disease: A regulatory viewpoint","volume":"23","author":"Mani","year":"2004","journal-title":"Stat. Med"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.expneurol.2004.06.027","article-title":"Induction of GABAergic phenotype in a neural stem cell line for transplantation in an excitotoxic model of Huntington\u2019s disease","volume":"190","author":"Bosch","year":"2004","journal-title":"Exp. Neurol"},{"key":"ref_33","first-page":"466","article-title":"Directed mobilization of endogenous neural progenitor cells: the intersection of stem cell biology and gene therapy","volume":"6","author":"Goldman","year":"2004","journal-title":"Curr. Opin. Mol. Ther"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.parkreldis.2004.02.013","article-title":"Harnessing endogenous stem cells to treat neurodegenerative disorders of the basal ganglia","volume":"10","author":"Mohapel","year":"2004","journal-title":"Parkinsonism Relat. Disord"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1126\/science.7434023","article-title":"Is your brain really necessary?","volume":"210","author":"Lewin","year":"1980","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0306-4522(02)00025-8","article-title":"Nervous system reorganization following injury","volume":"111","author":"Chen","year":"2002","journal-title":"Neurosci"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrn1587","article-title":"Modulation of neurodegeneration by molecular chaperones","volume":"6","author":"Muchowski","year":"2005","journal-title":"Nat. Rev. Neurosci"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neuint.2004.03.007","article-title":"Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer\u2019s disease","volume":"45","author":"Hynd","year":"2004","journal-title":"Neurochem. Int"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0896-6273(02)00794-8","article-title":"Inflammation in neurodegenerative disease: A double-edged sword","volume":"35","author":"Mucke","year":"2002","journal-title":"Neuron"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20624","article-title":"Mitochondria take center stage in aging and neurodegeneration","volume":"58","author":"Beal","year":"2005","journal-title":"Ann Neurol"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/CS20050148","article-title":"Pharmaceutical, cellular and genetic therapies for Huntington\u2019s disease","volume":"110","author":"Handley","year":"2006","journal-title":"Clin. Sci"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tins.2004.08.008","article-title":"Genetic mouse models of Huntington\u2019s and Parkinson\u2019s diseases: illuminating but imperfect","volume":"27","author":"Levine","year":"2004","journal-title":"Trends Neurosci"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cell.2005.01.015","article-title":"Environmental enrichment reduces A levels and amyloid deposition in transgenic mice","volume":"120","author":"Lazarov","year":"2005","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1440-1681.2005.04313.x","article-title":"Gene\u2013environment interactions, neuronal dysfunction and pathological plasticity in Huntington\u2019s disease","volume":"32","author":"Grote","year":"2005","journal-title":"Clin. Exp. Pharmacol. Physiol"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer\u2019s disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc. Natl Acad. Sci"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-2236(03)00038-9","article-title":"Presymptomatic compensation in Parkinson\u2019s disease is not dopamine-mediated","volume":"26","author":"Bezard","year":"2003","journal-title":"Trends Neurosci"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1017\/S1355617702813248","article-title":"What is cognitive reserve? Theory and research application of the reserve concept","volume":"8","author":"Stern","year":"2002","journal-title":"J. Int. Neuropsychol. Soc"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2004.09.006","article-title":"Memory and executive function in aging and AD: Multiple factors that cause decline and reserve factors that compensate","volume":"44","author":"Buckner","year":"2004","journal-title":"Neuron"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nn988","article-title":"Routes to remembering: the brains behind superior memory","volume":"6","author":"Maguire","year":"2003","journal-title":"Nat. Neurosci"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.tins.2005.02.001","article-title":"Neurovascular mechanisms of Alzheimer\u2019s neurodegeneration","volume":"28","author":"Zlokovic","year":"2005","journal-title":"Trends Neurosci"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/MCB.20.6.2260-2268.2000","article-title":"Compensation by fibroblast growth factor 1 (fgf1) does not account for the mild phenotypic defects observed in fgf2 null mice","volume":"20","author":"Miller","year":"2000","journal-title":"Mol. Cell. Biol"},{"key":"ref_52","first-page":"4213","article-title":"Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice","volume":"17","author":"Dono","year":"1998","journal-title":"Embryo J"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.7809630","article-title":"Requirement of FGF-4 for post-implantation mouse development","volume":"267","author":"Feldman","year":"1995","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1101\/gad.11.16.2040","article-title":"A role for FGF-6 in skeletal muscle regeneration","volume":"11","author":"Floss","year":"1997","journal-title":"Genes Dev"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1073\/pnas.95.10.5672","article-title":"Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2","volume":"95","author":"Ortega","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/nn1352","article-title":"Similar network activity from disparate circuit parameters","volume":"7","author":"Prinz","year":"2004","journal-title":"Nat. Neurosci"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinsons disease with ropinirole versus levodopa","volume":"54","author":"Whone","year":"2003","journal-title":"Ann. Neurol"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2307\/3350099","article-title":"Etimated prevalence of Alzheimer\u2019s disease in the United States","volume":"68","author":"Evans","year":"1990","journal-title":"Milbank Q"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nature05289","article-title":"A network dysfunction perspective on neurodegenerative diseases","volume":"443","author":"Palop","year":"2006","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/awh009","article-title":"Novel presenilin 1 mutation with profound neurofibrillary pathology in an indigenous Southern African family with early-onset Alzheimer\u2019s disease","volume":"127","author":"Heckmann","year":"2004","journal-title":"Brain"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.expneurol.2006.01.034","article-title":"Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington\u2019s disease","volume":"199","author":"Vazey","year":"2006","journal-title":"Exp. Neurol"},{"key":"ref_62","first-page":"231","article-title":"Human umbilical cord blood cells ameliorate Huntington\u2019s disease in transgenic mice","volume":"32","author":"Ende","year":"2001","journal-title":"J. Med"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/00207450390207759","article-title":"Autologous adult bone marrow stem cell transplantation in an animal model of huntington\u2019s disease: behavioral and morphological outcomes","volume":"113","author":"Lescaudron","year":"2003","journal-title":"Int. J. Neurosci"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14712598.4.2.121","article-title":"Transplantation of human umbilical cord blood cells in the repair of CNS diseases","volume":"4","author":"Newman","year":"2004","journal-title":"Expert Opin. Biol. Ther"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: A Delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2005.01202.x","article-title":"Cost of disorders of the brain in Europe","volume":"12","author":"Wittchen","year":"2005","journal-title":"Eur. J. Neurol"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1468-1331.2005.01190.x","article-title":"Cost of dementia in Europe","volume":"12","author":"Berr","year":"2005","journal-title":"Eur. J. Neurol"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ana.410140502","article-title":"Senile dementia of the Alzheimer type","volume":"14","author":"Terry","year":"1983","journal-title":"Ann. Neurol"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.1092132","article-title":"The genetics of adult-onset neuropsychiatric disease: Complexities and conundra?","volume":"302","author":"Kennedy","year":"2003","journal-title":"Science"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurol"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/archneur.1994.00540210060013","article-title":"Clinical neuropathological correlations in Alzheimer\u2019s disease and related dementias","volume":"51","author":"Galasko","year":"1994","journal-title":"Arch. Neurol"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kosunen, O, Soininen, H, Palj\u00e4rvi, L, Heinonen, O, Talasniemi, S, and Riekkinen, PJ (1991). Diagnostic accuracy of Alzheimer\u2019s disease: a neuropathological study. Acta Neuropathol (Berl), 185\u2013193.","DOI":"10.1007\/s004010050412"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer\u2019s disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1212\/WNL.51.1_Suppl_1.S2","article-title":"Alzheimer\u2019s disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities","volume":"51","author":"Cummings","year":"1998","journal-title":"Neurology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/gerona\/51A.6.M313","article-title":"Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia","volume":"51","author":"Larson","year":"1996","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00002093-199601040-00002","article-title":"Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology","volume":"10","author":"Rasmusson","year":"1996","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"ref_77","unstructured":"American Psychiatric Association DSM-IV (1994). Diagnostic and Statistical Manual, American Psychiatric Association. [4th Ed]."},{"key":"ref_78","unstructured":"International Classification of Diseases (ICD-10) (1992). Classification of Mental and Behavioural Disorders, World Health Organization. [10th Ed]."},{"key":"ref_79","first-page":"93","article-title":"Mild cognitive impairment: transition between aging and Alzheimer\u2019s disease","volume":"15","author":"Petersen","year":"2000","journal-title":"Neurologia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1001\/jama.1995.03520400044042","article-title":"Apolipoprotein E status as a predictor of the development of Alzheimer\u2019s disease in memory-impaired individuals","volume":"273","author":"Petersen","year":"1995","journal-title":"JAMA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch. Neurol"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0361-9230(03)00067-4","article-title":"Causative and susceptibility genes for Alzheimer\u2019s disease: A review","volume":"61","author":"Rocchi","year":"2003","journal-title":"Brain Res. Bull"},{"key":"ref_83","unstructured":"Niew\u00f6hner, J, and Tannert, C (2006). Gene therapy: Prospective technology assessment in its societal context, Elsevier Science. [1st ed]."},{"key":"ref_84","unstructured":"Peterson, J Available online: http:\/\/www.jax.org\/news\/balance_gene_defect.html, accessed 2008."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/sj.emboj.7601953","article-title":"Lipids revert inert A\u03b2-amyloid fibrils to neurotoxic protofibrils that affect learning in mice","volume":"27","author":"Martins","year":"2008","journal-title":"EMBO J"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.1_Suppl_1.S2","article-title":"Alzheimer\u2019s disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities","volume":"51","author":"Cummings","year":"1998","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.med.50.1.57","article-title":"The ubiquitin\u2013proteasome pathway and pathogenesis of human diseases","volume":"50","author":"Schwartz","year":"1999","journal-title":"Annu. Rev. Med"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1046\/j.0953-816x.2001.01604.x","article-title":"Oligodendroglial tau filament formation in transgenic mice expressing G272V tau","volume":"13","author":"Gotz","year":"2001","journal-title":"Eur. J. Neurosci"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/11154","article-title":"Amyloid production and deposition in mutant amyloid presursor protein and presenilin-1 yeast artificial chromosome transgenic mice","volume":"2","author":"Lamb","year":"1999","journal-title":"Nat. Neurosci"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev.pharmtox.43.100901.140248","article-title":"Alzheimer\u2019s disease: molecular understanding predicts amyloid-based therapeutics","volume":"43","author":"Selkoe","year":"2003","journal-title":"Ann. Rev. Pharmacol. Toxicol"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/archneur.59.11.1759","article-title":"Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain","volume":"59","author":"Lleo","year":"2002","journal-title":"Arch. Neurol"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jnen\/63.8.821","article-title":"Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology","volume":"63","author":"Cataldo","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0002-9440(10)65494-6","article-title":"Tau pathology generated by over expression of tau","volume":"155","author":"Iqbal","year":"1999","journal-title":"Am. J. Pathol"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ana.410260308","article-title":"Tau in situ hybridization in normal and Alzheimer brain: localization in the somatodendritic compartment","volume":"26","author":"Kosik","year":"1989","journal-title":"Ann. Neurol"},{"key":"ref_95","first-page":"123","article-title":"Tau protein immunoreactivity in dementia of the Alzheimer type. I. Morphology, evolution, distribution, and pathogenetic implications","volume":"60","author":"Papasozomenos","year":"1989","journal-title":"Lab Invest"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbadis.2004.06.018","article-title":"Tau alteration and neuronal degeneration in tauopathies: mechanisms and models","volume":"1739","author":"Brandt","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molmed.2005.02.009","article-title":"Alzheimer\u2019s disease: Abeta, tau and synaptic dysfunction","volume":"11","author":"LaFerla","year":"2005","journal-title":"Trends Mol. Med"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1750-3639.1991.tb00661.x","article-title":"Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections","volume":"1","author":"Braak","year":"1991a","journal-title":"Brain Pathol"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta. Neuropathol. (Berl)"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.mehy.2004.02.032","article-title":"Brain cholinesterases: I. The clinico-histopathological and biochemical basis of Alzheimer\u2019s disease","volume":"63","author":"Shen","year":"2004","journal-title":"Med. Hypoth"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer\u2019s disease","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neulet.2004.03.008","article-title":"Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer\u2019s disease","volume":"362","author":"Zhang","year":"2004","journal-title":"Neurosci. Lett"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1474-4422(04)00878-6","article-title":"Dietary factors and Alzheimer\u2019s disease","volume":"3","author":"Luchsinger","year":"2004","journal-title":"Lancet Neurol"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cnur.2004.02.012","article-title":"The evolving role of genomics in shaping care for persons with dementia","volume":"39","author":"Schutte","year":"2004","journal-title":"Nurs. Clin. North Am"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cnur.2004.02.010","article-title":"Overview of Alzheimer\u2019s disease","volume":"39","author":"Souder","year":"2004","journal-title":"Nurs. Clin. North Am"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev.cellbio.18.020402.142302","article-title":"A cell biological perspective on Alzheimer\u2019s disease","volume":"18","author":"Annaert","year":"2002","journal-title":"Ann. Rev. Cell Dev. Biol"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biocel.2004.07.009","article-title":"The role of inflammation in Alzheimer\u2019s disease","volume":"37","author":"Tuppo","year":"2005","journal-title":"Int. J. Biochem. Cell Biol"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.102.035048","article-title":"Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention","volume":"304","author":"Liu","year":"2003","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00019442-200303000-00008","article-title":"Non-Steroidal Anti-Inflammatory Drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients","volume":"11","author":"Landi","year":"2003","journal-title":"Am. J. Geriatr. Psych"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1359-6446(04)03120-4","article-title":"Neurodegenerative disease research in the 21st century","volume":"9","author":"Bale","year":"2004","journal-title":"Drug Disc. Today"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2174\/1389450043345272","article-title":"Metal and inflammatory targets for Alzheimer\u2019s disease","volume":"5","author":"Rogers","year":"2004","journal-title":"Curr. Drug Targ"},{"key":"ref_113","unstructured":"Ghorpade, A To investigate the role of glial cells in central nervous system inflammation and neurodegeneration. University of Nebraska Medical Center, Department of Pharmacology and Experimental Neuroscience (http:\/\/www.unmc.edu\/dept\/pharmacology\/index.cfm?CONREF=68)."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/jnr.20787","article-title":"Novel role of TGF-\u03b2 in differential astrocyte-TIMP-1 regulation: Implications for HIV-1-dementia and neuroinflammation","volume":"83","author":"Dhar","year":"2006","journal-title":"J. Neurosci. Res"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1471-4914(03)00031-5","article-title":"Protein carbonylation in human diseases","volume":"9","author":"Giustarini","year":"2003","journal-title":"Trends Mol. Med"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchromb.2005.04.023","article-title":"Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview","volume":"827","author":"Mariani","year":"2005","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.neurobiolaging.2004.09.020","article-title":"Peripheral biomarkers of oxidative damage in Alzheimer\u2019s disease: The road ahead","volume":"26","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"ref_118","first-page":"143","article-title":"Metal ions and oxidative protein modification in neurological disease","volume":"41","author":"Sayre","year":"2005","journal-title":"Ann. Ist. Super. Sanita"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neuint.2004.03.007","article-title":"Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer\u2019s disease","volume":"45","author":"Hynd","year":"2004","journal-title":"Neurochem. Int"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/jcbfm.1981.18","article-title":"Cell damage in the brain: A speculative synthesis","volume":"1","year":"1981","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0361-9230(00)00369-5","article-title":"Role of calcium in neuronal cell injury: Which subcellular compartment is involved?","volume":"53","author":"Paschen","year":"2000","journal-title":"Brain Res. Bull"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchemneu.2003.12.004","article-title":"Induction of neuronal death by ER stress in Alzheimer\u2019s disease","volume":"28","author":"Katayama","year":"2004","journal-title":"J. Chem. Neuroanat"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mrfmmm.2004.06.056","article-title":"ER stress and the unfolded protein response","volume":"569","author":"Kaufman","year":"2005","journal-title":"Mutat. Res"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1023\/A:1025682611389","article-title":"Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases","volume":"28","author":"Rego","year":"2003","journal-title":"Neurochem. Res"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrn960","article-title":"Calcium dyshomeostasis and intracellular signalling in Alzheimer\u2019s disease","volume":"3","author":"LaFerla","year":"2002","journal-title":"Nat. Rev. Neurosci"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/1568007054546117","article-title":"Alzheimer\u2019s disease associated neurotoxic mechanisms and neuroprotective strategies","volume":"4","author":"Pereira","year":"2005","journal-title":"Curr. Drug Targ. CNS Neurol. Disord"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/hmg\/9.3.353","article-title":"Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice","volume":"9","author":"Hamanaka","year":"2000","journal-title":"Human Mol. Gen"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000058332","article-title":"Candidate gene association studies in sporadic Alzheimer\u2019s disease","volume":"14","author":"Combarros","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1073\/pnas.90.17.7951","article-title":"Apoptosis is induced by beta-amyloid in cultured central nervous system neurons","volume":"90","author":"Loo","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1097\/00001756-199412000-00031","article-title":"Immunohistochemical evidence for apoptosis in Alzheimer\u2019s disease","volume":"5","author":"Su","year":"1994","journal-title":"Neuroreport"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/exnr.1995.1025","article-title":"Evidence for apoptotic cell death in Alzheimer\u2019s disease","volume":"133","author":"Smale","year":"1995","journal-title":"Exp. Neurol"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.2000.0740001.x","article-title":"Apoptosis and the nervous system","volume":"74","author":"Sastry","year":"2000","journal-title":"J. Neurochem"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1471-4159.2004.02452.x","article-title":"In vivo inhibition of A\u03b2 production by Memapsin 2 (\u03b2-secretase) inhibitors","volume":"89","author":"Chang","year":"2004","journal-title":"J. Neurochem"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3233\/JAD-2004-6601","article-title":"(+\/\u2013)-huprine Y, (\u2013)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration","volume":"6","author":"Jorda","year":"2004","journal-title":"J. Alzheimers Dis"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2318-5-3","article-title":"Rivastigmine: An open-label, observational study of safety and effectiveness in treating patients with Alzheimer\u2019s disease for up to 5 years","volume":"5","author":"Farlow","year":"2005","journal-title":"BMC Geriatr"},{"key":"ref_136","unstructured":"National Institute on Aging (NIA) Available online: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00000172?term=Alzheimer's+Disease&rank=51, accessed 2008."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cger.2003.11.002","article-title":"Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease and related dementias","volume":"20","author":"Masterman","year":"2004","journal-title":"Clin. Geriatr. Med"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(04)16533-1","article-title":"AD2000: donepezil in Alzheimer\u2019s disease","volume":"363","author":"Schneider","year":"2004","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"ref_140","first-page":"135","article-title":"Memantine in severe dementia: results of the 9M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine)","volume":"14","author":"Winblad","year":"1999","journal-title":"Psychiatry"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/02646830500382037","article-title":"Clinical aspects of inflammation in Alzheimer\u2019s disease","volume":"17","author":"Rosenberg","year":"2005","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_142","first-page":"375","article-title":"Vaccination therapy for Alzheimer\u2019s disease","volume":"59","author":"Tabira","year":"2007","journal-title":"Brain Nerve"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid- beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0306-4522(01)00488-2","article-title":"Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture","volume":"109","author":"Jeyarasasingam","year":"2002","journal-title":"Neuroscience"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.1999.07.604","article-title":"Parkinson\u2019s disease-the shaking palsy, underlying factors, diagnostic considerations, and clinical course","volume":"106","author":"Conley","year":"1999","journal-title":"Postgrad. Med"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/35081564","article-title":"Alpha-synuclein and neurodegenerative diseases","volume":"2","author":"Goedert","year":"2001","journal-title":"Nat. Rev. Neurosci"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1385\/JMN:24:3:343","article-title":"The role of \u03b1-synuclein assembly and metabolism in the pathogenesis of lewy body disease","volume":"24","author":"Hashimoto","year":"2004","journal-title":"J. Mol. Neurosci"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1385\/JMN:24:3:417","article-title":"New aspects of genetic contributions to Parkinson\u2019s disease","volume":"24","author":"Hofer","year":"2004","journal-title":"J. Mol. Neurosci"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1046\/j.1432-1327.2000.01595.x","article-title":"Glutathione, oxidative stress and neurodegeneration","volume":"267","author":"Schulz","year":"2001","journal-title":"Eur. J. Biochem"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0278-5846(02)00339-1","article-title":"Alpha-synuclein, Abeta and Alzheimer\u2019s disease","volume":"27","author":"Wirths","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psych"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1385\/JMN:24:3:425","article-title":"Pathological proteins in Parkinson\u2019s disease: focus on the proteasome","volume":"24","author":"Snyder","year":"2004","journal-title":"J. Mol. Neurosci"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"53","DOI":"10.14789\/pjmj.47.53","article-title":"Familial Parkinson\u2019s disease based on the single gene defects. A key to the understanding the pathogenesis for nigral degeneration in sporadic Parkinson\u2019s disease","volume":"47","author":"Nobutaka","year":"2001","journal-title":"Juntendo Med. J"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_155","unstructured":"Dickson, DW (2003). Neurodegeneration and Dementias, ISN Press."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations","volume":"20","author":"Bernheimer","year":"1973","journal-title":"J. Neurol. Sci"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/syn.1042","article-title":"F-18FDOPA and F-18CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson\u2019s disease","volume":"40","author":"Rinne","year":"2001","journal-title":"Synapse"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0301-0082(99)00067-2","article-title":"Functional changes of the basal ganglia circuitry in Parkinson\u2019s disease","volume":"62","author":"Blandini","year":"2000","journal-title":"Prog. Neurobiol"},{"key":"ref_159","first-page":"122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann. Neurol"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci"},{"key":"ref_161","first-page":"19","article-title":"Basal ganglia and Parkinson disease: An anatomical perspective","volume":"2","author":"Parent","year":"1999","journal-title":"Neurosci. News"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ana.1119","article-title":"Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models","volume":"50","author":"Freeman","year":"2001","journal-title":"Ann. Neurol"},{"key":"ref_163","unstructured":"Jankovic, JJ, and Tolosa, E (2002). Parkinson\u2019s Disease and Movement Disorders, Lippincott Williams and Wilkins. [4th Ed]."},{"key":"ref_164","first-page":"1381","article-title":"Protein folding diseases and neurodegeneration: Lessons learned from yeast","volume":"1783","author":"Winderickx","year":"2008","journal-title":"Mol. Cell Res"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1196\/annals.1306.019","article-title":"Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases","volume":"1012","author":"Bartzokis","year":"2004","journal-title":"Ann. New York Acad. Sci"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbadis.2004.05.007","article-title":"Electrochemical investigation into the redox activity of Fe(II)\/Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases","volume":"690","author":"Bridge","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","article-title":"The A53T \u03b1-synuclein mutation increases iron-dependent aggregation and toxicity","volume":"20","author":"Petrucelli","year":"2000","journal-title":"J. Neurosci"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00002512-200118090-00004","article-title":"Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment","volume":"18","author":"Halliwell","year":"2000","journal-title":"Drugs Aging"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.1090439","article-title":"Yeast cells provide insight into alpha-synuclein biology and pathobiology","volume":"302","author":"Outeiro","year":"2003","journal-title":"Science"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0306-4522(01)00113-0","article-title":"Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome-sensitive inclusions in primary neurons","volume":"104","author":"McLean","year":"2001","journal-title":"Neuroscience"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"34328","DOI":"10.1074\/jbc.M004345200","article-title":"\u03b1-synuclein membrane interactions and lipid specificity","volume":"275","author":"Jo","year":"2000","journal-title":"J. Biol. Chem"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00415-004-1704-5","article-title":"Neuroimaging trials of Parkinson\u2019s disease progression","volume":"251","author":"Seibyl","year":"2004","journal-title":"J. Neurol"},{"key":"ref_173","unstructured":"Factor, SA, and Weiner, WJ (2000). Parkinson\u2019s Disease Diagnosis and Clinical Management, Demos Medical Publishing, Inc."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1212\/01.WNL.0000052681.28286.52","article-title":"Initial agonist treatment of Parkinson disease","volume":"60","author":"Albin","year":"2003","journal-title":"Neurol"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of L-dopa: Why is it the gold standard Parkinson\u2019s disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol. Sci"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/pgmj.2003.013912","article-title":"Long term motor complications of levodopa: Clinical features, mechanisms, and management strategies","volume":"80","author":"Thanvi","year":"2004","journal-title":"Postgrad. Med. J"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-7091-0579-5_10","article-title":"Transdermal lisuride delivery in the treatment of Parkinson\u2019s disease","volume":"68","author":"Woitalla","year":"2004","journal-title":"J. Neural. Transm. Suppl"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00002512-200522010-00006","article-title":"Rasagiline","volume":"22","author":"Siddiqui","year":"2005","journal-title":"Drugs Aging"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ptr.1486","article-title":"Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson\u2019s disease","volume":"18","author":"Kim","year":"2004","journal-title":"Phytother. Res"},{"key":"ref_180","first-page":"948","article-title":"Future of gene therapy for Parkinson\u2019s disease","volume":"44","author":"Mochizuki","year":"2004","journal-title":"Rinsho Shinkeigaku"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1385\/JMN:24:3:353","article-title":"Embryonic and adult stem cells as a source for cell therapy in Parkinson\u2019s disease","volume":"24","author":"Levy","year":"2004","journal-title":"J. Mol. Neurosci"},{"key":"ref_182","unstructured":"Karimi and Eftekharpour Fehlings lab, McEwen Centre for Regenerative Medicine. Available online: www.mcewencentre.com\/res_prog_scnd.asp, accessed 2009."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archneur.61.6.919","article-title":"Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with lewy bodies","volume":"61","author":"Fenwick","year":"2004","journal-title":"Arch. Neurol"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study","volume":"6","author":"McKeith","year":"2004","journal-title":"Lancet Neurol"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1172\/JCI117946","article-title":"Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson\u2019s disease","volume":"95","author":"Walkinshaw","year":"1995","journal-title":"J. Clin. Invest"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.10427","article-title":"Plasticity of the nigropallidal pathway in Parkinson\u2019s disease","volume":"53","author":"Whone","year":"2003","journal-title":"Ann. Neurol"},{"key":"ref_187","first-page":"231","article-title":"Ropinirole in the symptomatic treatment of Parkinson\u2019s disease","volume":"45","author":"Brooks","year":"1995","journal-title":"J. Neural. Transm. Suppl"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.46.6.1551","article-title":"Amantadine treatment is an independent predictor of improved survival in Parkinson\u2019s disease","volume":"46","author":"Uitti","year":"1996","journal-title":"Neurology"},{"key":"ref_189","unstructured":"Ebadi, MS, and Pfeiffer, R (2005). Amantadine neuroprotective effect on PD. Parkinson\u2019s Dis, 686."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/pmj.76.900.602","article-title":"Pharmacological treatment of Parkinson\u2019s disease","volume":"76","author":"Bhatia","year":"2000","journal-title":"Postgrad. Med. J"},{"key":"ref_191","unstructured":"Brandt, T, Caplan, LR, and Dichgans, J (1996). Parkinsonism, Academic Press."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (1997). Entacapone improves motor fluctuations in levodopa-treated Parkinson\u2019s disease patients. Ann. Neurol, 42, 747\u2013755.","DOI":"10.1002\/ana.410420511"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/jnnp.63.2.228","article-title":"Autonomic effects of selegeline: Possible cardiovascular toxicity in Parkinson\u2019s disease","volume":"63","author":"Churchyard","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/archneur.1967.00470260014002","article-title":"Cholinergic-anticholinergic antagonisms in parkinsonism","volume":"17","author":"Duvoisin","year":"1967","journal-title":"Arch Neurol"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF00886877","article-title":"Anticholinergic therapy and dementia in patients with Parkinson\u2019s disease","volume":"243","author":"Pondal","year":"1996","journal-title":"J. Neurol"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0306-3623(94)90082-5","article-title":"General properties and clinical possibilities of new selective inhibitors of catechol-o-methyltransferase","volume":"25","author":"Kaakkola","year":"1994","journal-title":"Gen. Pharmacol"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00002826-199304000-00007","article-title":"The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers","volume":"16","author":"Gordin","year":"1993","journal-title":"Clin. Neuropharmacol"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease","volume":"344","author":"Freed","year":"2001","journal-title":"N. Engl. J. Med"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1006\/exnr.1997.6577","article-title":"Outcome following intrastriatal fetal mesencephalic grafts for Parkinson\u2019s patients is directly related to the volume of grafted tissue","volume":"146","author":"Kopyov","year":"1997","journal-title":"Exp. Neurol"},{"key":"ref_201","first-page":"1395","article-title":"Long-term follow-up in 10 Parkinson\u2019s disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: The Clinica Puerta de Hierro experience. CPH Neural Transplantation Group","volume":"27","author":"Bravo","year":"1995","journal-title":"Transplant Proc"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann. Neurol"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/WNL.46.5.1442","article-title":"Relationship of the Tufts Quantitative Neuromuscular Exam(TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS","volume":"46","author":"McGuire","year":"1996","journal-title":"Neurol"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(95)91556-7","article-title":"Is senile dementia \u201cage-related\u201d or \u201cageing-related\u201d? Evidence from meta-analysis of dementia prevalence in the oldest old","volume":"346","author":"Ritchie","year":"1995","journal-title":"Lancet"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJM197305172882005","article-title":"Epidemiology of motor-neuron diseases","volume":"288","author":"Bobowick","year":"1973","journal-title":"N. Engl. J. Med"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1212\/WNL.55.9.1358","article-title":"Parkinson\u2019s disease and parkinsonism in a longitudinal study: Twofold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging","volume":"55","author":"Baldereschi","year":"2000","journal-title":"Neurology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/jnnp.53.12.1043","article-title":"Clinical features and associations of 560 cases of motor neuron disease","volume":"53","author":"Li","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14660820052415871","article-title":"Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS Care Study Group","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0022-510X(98)00193-2","article-title":"Diagnosis of amyotrophic lateral sclerosis","volume":"160","author":"Rowland","year":"1998","journal-title":"J. Neurol. Sci"},{"key":"ref_210","first-page":"537","article-title":"Patient resistance and prognosis in amyotrophic lateral sclerosis","volume":"51","author":"Mulder","year":"1976","journal-title":"MayoClin. Proc"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00313868","article-title":"Amyotrophic lateral sclerosis. A study of its presentation and prognosis","volume":"232","author":"Gubbay","year":"1985","journal-title":"J. Neurol"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/14660820410017091","article-title":"Temporal gene expression patterns in G93A\/SOD1 mouse","volume":"5","author":"Chen","year":"2004","journal-title":"Amyotroph. Lateral. Scler. Other Motor Neuron Disord"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/14660820310011700","article-title":"Sixteen novel mutations in the Cu\/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: A decade of discoveries, defects and disputes","volume":"4","author":"Andersen","year":"2003","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199205283262204","article-title":"Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis","volume":"326","author":"Rothstein","year":"2002","journal-title":"N. Eng. J. Med"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0387-7604(02)00103-1","article-title":"Oxidative stress and disturbed glutamate transport in spinal muscular atrophy","volume":"24","author":"Hayashi","year":"2002","journal-title":"Brain Dev"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-510X(01)00661-X","article-title":"Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients","volume":"193","author":"Bensimon","year":"2002","journal-title":"J. Neurol. Sci"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/hmg\/ddg267","article-title":"Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice","volume":"12","author":"Guo","year":"2003","journal-title":"Hum. Mol. Genet"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0404.1997.tb00079.x","article-title":"Autoimmunity and ALS: Studies on antibodies to acetylcholinesterase in sera","volume":"95","author":"Haggstrom","year":"1997","journal-title":"Acta. Neurol. Scand"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1517\/14656566.5.4.735","article-title":"Current pharmacological management of Amyotrophic Lateral Sclerosis and a role for rational polypharmacy","volume":"5","author":"Weiss","year":"2004","journal-title":"Exp. Opin. Pharmacother"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.conb.2007.08.005","article-title":"TDP-43: A novel neurodegenerative proteinopathy","volume":"17","author":"Forman","year":"2007","journal-title":"Curr. Opin. Neurobiol"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ana.21425","article-title":"Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"64","author":"Hasegawa","year":"2008","journal-title":"Ann. Neurol"},{"key":"ref_222","first-page":"513","article-title":"The symptomatic treatment of amyotrophic lateral sclerosis","volume":"148","author":"Kampelmacher","year":"2004","journal-title":"Ned. Tijdschr. Geneeskd"},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Miller, RG, Mitchell, JD, Lyon, M, and Moore, DH (2007). Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev, 1, No. CD001447. DOI: 10.1002\/14651858.CD001447.","DOI":"10.1002\/14651858.CD001447.pub2"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ng0592-99","article-title":"The Huntington\u2019s disease candidate region exhibits many different haplotypes","volume":"1","author":"MacDonald","year":"1992","journal-title":"Nat. Genet"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"11635","DOI":"10.1074\/jbc.M412042200","article-title":"Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes","volume":"280","author":"Jana","year":"2005","journal-title":"J. Biol. Chem"},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is unstable on Huntington\u2019s disease chromosomes. Cell, 72, 971\u2013983.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"ref_227","first-page":"16","article-title":"Phenotypic characterization of individuals with 30\u201340 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u201339 repeats","volume":"59","author":"Rubinsztein","year":"1996","journal-title":"Am. J. Hum. Genet"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s004390050432","article-title":"Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage","volume":"99","author":"Sathasivam","year":"1997","journal-title":"Hum. Genet"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/hmg\/3.1.85","article-title":"Sequence of the murine Huntington\u2019s disease gene: evidence for conservation, and polymorphism in a triplet (CCG) repeat alternate splicing","volume":"3","author":"Lin","year":"1994","journal-title":"Hum. Mol. Genet"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/ng0595-67","article-title":"Comparative sequence analysis of the human and puffer fish Huntington\u2019s disease gene","volume":"10","author":"Baxendale","year":"1995","journal-title":"Nat. Genet"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-6-1","article-title":"Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation","volume":"6","author":"Wang","year":"2005","journal-title":"BMC Neurosci"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.neuroscience.2006.10.056","article-title":"Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases","volume":"145","author":"Trushina","year":"2007","journal-title":"Neuroscience"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00005072-199111000-00005","article-title":"Decreased neuronal and increased oligo dendroglial densities in Huntington\u2019s disease caudate nucleus","volume":"50","author":"Myers","year":"1991","journal-title":"J. Neuropathol. Exp. Neurol"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00005072-198809000-00003","article-title":"Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatumin Huntington\u2019s disease","volume":"47","author":"Vonsattel","year":"1988","journal-title":"J. Neuropathol. Exp. Neurol"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s004390050432","article-title":"Identification of an HD patient with a (CAG) 180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage","volume":"99","author":"Sathasivam","year":"1997","journal-title":"Hum Genet"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/hmg\/8.9.1807","article-title":"A putative Drosophila homolog of the Huntington\u2019s disease gene","volume":"8","author":"Li","year":"1999","journal-title":"Hum. Mol. Genet"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ng1095-115","article-title":"HEAT repeats in the Huntington\u2019s disease protein [letter]","volume":"11","author":"Andrade","year":"1995","journal-title":"Nat Genet"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/hmg\/6.3.487","article-title":"HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system","volume":"6","author":"Wanker","year":"1997","journal-title":"Hum Mol Genet"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1083\/jcb.122.3.635","article-title":"Synthetic-lethal interactions identify two novel genes, SLA1 and SLA2, that controls membrane cytoskeleton assembly in Saccharomyces erevisiae","volume":"122","author":"Holtzman","year":"1993","journal-title":"J. Cell Biol"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1091\/mbc.8.11.2291","article-title":"End4p\/Sla2p interacts with actin-associated proteins for endocytosis in Saccharomyces cerevisiae","volume":"8","author":"Wesp","year":"1997","journal-title":"Mol Biol Cell"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/exnr.1998.6832","article-title":"Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways","volume":"152","author":"Velier","year":"1998","journal-title":"Exp. Neurol"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1083\/jcb.147.7.1503","article-title":"An actin-binding protein of the Sla2\/Huntingtin interacting protein 1 family is a novel component of lathrin-coated pits and vesicles","volume":"147","author":"Kessels","year":"1999","journal-title":"J Cell Biol"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/378398a0","article-title":"A huntingtin-associated protein enriched in brain with implications for pathology","volume":"378","author":"Li","year":"1995","journal-title":"Nature"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/00001756-199707070-00031","article-title":"Fast transport and retrograde movement of huntingtin and HAP 1 in axons","volume":"8","author":"Chase","year":"1997","journal-title":"Neuroreport"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/hmg\/6.13.2205","article-title":"Huntingtin-associated protein1 (HAP1) interacts with the p150 glued subunit of dynactin","volume":"6","author":"Engelender","year":"1997","journal-title":"Hum Mol Genet"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","article-title":"A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease","volume":"37","author":"Giorgini","year":"2005","journal-title":"Nat. Genet"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington\u2019s disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","article-title":"Symptomatic treatment of Huntington\u2019s disease","volume":"5","author":"Adam","year":"2008","journal-title":"Neurotherapeutics"},{"key":"ref_249","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington\u2019s disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsych Neuropsychol Behav Neurol"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0004-282X2004000600030","article-title":"Functional and motor response to low dose olanzapine in Huntington\u2019s disease: Case report","volume":"62","author":"Laks","year":"2004","journal-title":"Arq. Neuropsiquiatr"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington\u2019s disease with olanzapine and valproate","volume":"343","author":"Grove","year":"2001","journal-title":"N. Eng. J. Med"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3748\/wjg.v11.i5.764","article-title":"Acquired hepatocerebral degeneration: A case report","volume":"11","author":"Chen","year":"2005","journal-title":"World J. Gastroenterol"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ana.410400204","article-title":"Neurodegenerative disorders with extensive tau pathology: A comparative study and review","volume":"40","author":"Feany","year":"1996","journal-title":"Ann. Neurol"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neulet.2004.08.079","article-title":"Immunolocalization of 14\u20133-3 isoforms in brains with Pick body disease","volume":"371","author":"Umahara","year":"2004","journal-title":"Neurosci. Lett"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jneuroim.2006.03.010","article-title":"Altered maturation of circulating dendritic cells in primary progressive MS patients","volume":"175","author":"Comabella","year":"2006","journal-title":"J. Neuroimmunol"},{"key":"ref_256","first-page":"48","article-title":"Managing bladder symptoms in people with multiple sclerosis","volume":"101","author":"Haslam","year":"2005","journal-title":"Nurs. Times"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00019052-199906000-00008","article-title":"Axonal pathology in multiple sclerosis: relationship to neurologic disability","volume":"12","author":"Trapp","year":"1999","journal-title":"Curr. Opin. Neurol"},{"key":"ref_258","first-page":"1","article-title":"Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept","volume":"296","author":"Oldstone","year":"2005","journal-title":"Curr. Top. Microbiol. Immunol"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2004.035980","article-title":"Present and future drug treatment for Parkinson\u2019s disease","volume":"76","author":"Schapira","year":"2005","journal-title":"J. Neurol. Neurosurg. Psych"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.med.57.121304.131442","article-title":"Current pharmacotherapy for Alzheimer\u2019s disease","volume":"57","author":"Lleo","year":"2006","journal-title":"Ann. Rev. Med"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/1381612043386473","article-title":"Functional neurochemistry of Alzheimer\u2019s disease","volume":"10","author":"Gsell","year":"2004","journal-title":"Curr. Pharm. Des"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/0891988703258671","article-title":"Can Alzheimer\u2019s disease and dementias with Lewy bodies be distinguished clinically?","volume":"16","author":"Weiner","year":"2003","journal-title":"J. Geriatr. Psych. Neurol"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1528-1167.2006.00554.x","article-title":"Incidence and predictors of seizures in patients with Alzheimer\u2019s disease","volume":"47","author":"Amatniek","year":"2006","journal-title":"Epilepsia"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neulet.2004.05.107","article-title":"Increased seizure threshold and severity in young transgenic CRND8 mice","volume":"367","author":"Gold","year":"2004","journal-title":"Neurosci. Lett"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0197-4580(94)00150-2","article-title":"Anticonvulsants attenuate amyloid-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology","volume":"16","author":"Mark","year":"1995","journal-title":"Neurobiol. Aging"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nature02621","article-title":"Pathways towards and away from Alzheimer\u2019s disease","volume":"430","author":"Mattson","year":"2004","journal-title":"Nat"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"9686","DOI":"10.1523\/JNEUROSCI.2829-05.2005","article-title":"Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice","volume":"25","author":"Palop","year":"2005","journal-title":"J. Neurosci"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"9572","DOI":"10.1073\/pnas.1133381100","article-title":"Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer\u2019s disease-related cognitive deficits","volume":"100","author":"Palop","year":"2003","journal-title":"Proc. Natl Acad. Sci"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.10069","article-title":"Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment","volume":"51","author":"DeKosky","year":"2002","journal-title":"Ann. Neurol"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tins.2004.03.006","article-title":"Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer\u2019s disease?","volume":"27","author":"Small","year":"2004","journal-title":"Trends Neurosci"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1212\/01.wnl.0000171450.97464.49","article-title":"Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD","volume":"65","author":"Dickerson","year":"2005","journal-title":"Neurology"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/107175401750177061","article-title":"Controlled release tacrine delivery system for the treatment of Alzheimer\u2019s disease","volume":"8","author":"Yang","year":"2001","journal-title":"Drug Deliv"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/bc034164r","article-title":"Nanogels for oligonucleotide delivery to the brain","volume":"15","author":"Vinogradov","year":"2004","journal-title":"Bioconjug. Chem"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1385\/JMN:20:3:339","article-title":"Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors","volume":"20","author":"Rice","year":"2003","journal-title":"J. Mol. Neurosci"},{"key":"ref_275","first-page":"1515","article-title":"Therapeutic use of stem cells. II. Adult stem cells","volume":"54","author":"Uzan","year":"2004","journal-title":"Rev. Prat"},{"key":"ref_276","unstructured":"Shoichet, M Shoichet lab, McEwen Centre for Regenerative Medicine."},{"key":"ref_277","unstructured":"Vernalis (Pty) Ltd V1512-Treatment of Parkinson\u2019s disease."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1586\/14737175.6.9.1275","article-title":"Rotigotine for the treatment of Parkinson\u2019s disease","volume":"6","author":"Morgan","year":"2006","journal-title":"Exp. Rev. Neurother"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.wnf.0000162228.00154.ba","article-title":"Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease","volume":"28","author":"Guldenpfennig","year":"2005","journal-title":"Clin. Neuropharmacol"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/10\/6\/2510\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:10:30Z","timestamp":1760220630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/10\/6\/2510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,3]]},"references-count":280,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,6]]}},"alternative-id":["i10062510"],"URL":"https:\/\/doi.org\/10.3390\/ijms10062510","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,3]]}}}